Do all patients with breast cancer require systemic adjuvant therapy?
作者信息
Griggs Jennifer J, Hayes Daniel F
出版信息
J Natl Cancer Inst. 2011 Sep 21;103(18):1350-1. doi: 10.1093/jnci/djr331. Epub 2011 Aug 31.
Abstract
摘要
相似文献
1
Do all patients with breast cancer require systemic adjuvant therapy?所有乳腺癌患者都需要全身辅助治疗吗？
J Natl Cancer Inst. 2011 Sep 21;103(18):1350-1. doi: 10.1093/jnci/djr331. Epub 2011 Aug 31.
2
Tamoxifen Breast Cancer Prevention Trial--an update.
Prog Clin Biol Res. 1997;396:271-82.
3
Can mammographic densities predict effects of tamoxifen on the breast?
J Natl Cancer Inst. 1996 Jan 17;88(2):128-9. doi: 10.1093/jnci/88.2.128-a.
4
Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst. 1999 Apr 21;91(8):730. doi: 10.1093/jnci/91.8.730.
5
[Tamoxifen and breast cancer: is everything known already?].[他莫昔芬与乳腺癌：一切都已为人所知了吗？]
Tumori. 1998 Nov-Dec;84(6):A1-5.
6
Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.关于：他莫昔芬预防乳腺癌：国家外科辅助乳腺和肠道项目P-1研究报告
J Natl Cancer Inst. 1999 Jan 20;91(2):188. doi: 10.1093/jnci/91.2.188.
7
Tamoxifen versus raloxifene in the prevention of breast cancer.他莫昔芬与雷洛昔芬预防乳腺癌的比较。
Eur J Cancer. 2002 Nov;38 Suppl 6:S20-1. doi: 10.1016/s0959-8049(02)00271-x.
8
Tamoxifen in early breast cancer.早期乳腺癌中的他莫昔芬
Lancet. 1998 Aug 1;352(9125):404-5. doi: 10.1016/s0140-6736(05)60503-x.
9
Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.他莫昔芬与芳香化酶抑制剂：2001年圣安东尼奥传来的消息
Cancer Control. 2001 Nov-Dec;8(6):478-9. doi: 10.1177/107327480100800601.
10
Breast cancer hopes.
Nurs Spectr (Wash D C). 1998 Jun 1;8(11):17-8.
本文引用的文献
1
Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.早期激素受体阳性乳腺癌患者的死亡率：丹麦基于人群的队列研究。
J Natl Cancer Inst. 2011 Sep 21;103(18):1363-72. doi: 10.1093/jnci/djr299. Epub 2011 Aug 31.
2
HER2 and hormone receptor-positive breast cancer--blocking the right target.人表皮生长因子受体 2 阳性和激素受体阳性乳腺癌——阻断正确的靶点。
Nat Rev Clin Oncol. 2011 May;8(5):307-11. doi: 10.1038/nrclinonc.2010.185. Epub 2010 Dec 14.
3
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.美国临床肿瘤学会临床实践指南：激素受体阳性乳腺癌患者辅助内分泌治疗的更新。
J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12.
4
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.应用 21 基因复发评分预测接受阿那曲唑或他莫昔芬治疗的绝经后激素受体阳性乳腺癌患者的无病生存和远处复发风险：TransATAC 研究。
J Clin Oncol. 2010 Apr 10;28(11):1829-34. doi: 10.1200/JCO.2009.24.4798. Epub 2010 Mar 8.
5
Ki67 in breast cancer: prognostic and predictive potential.Ki67 在乳腺癌中的：预后和预测潜能。
Lancet Oncol. 2010 Feb;11(2):174-83. doi: 10.1016/S1470-2045(09)70262-1.
6
Use of archived specimens in evaluation of prognostic and predictive biomarkers.存档标本在评估预后和预测生物标志物中的应用。
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.
7
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.与经典临床病理特征相比，21基因检测在激素受体阳性可手术乳腺癌中的预后效用。
J Clin Oncol. 2008 Sep 1;26(25):4063-71. doi: 10.1200/JCO.2007.14.4501. Epub 2008 Aug 4.
8
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.美国临床肿瘤学会2007年乳腺癌肿瘤标志物应用建议更新版。
J Clin Oncol. 2007 Nov 20;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364. Epub 2007 Oct 22.
9
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.他莫昔芬与雷洛昔芬对发生浸润性乳腺癌及其他疾病转归风险的影响：国家外科辅助乳腺和肠道项目（NSABP）他莫昔芬与雷洛昔芬研究（STAR）P-2试验
JAMA. 2006 Jun 21;295(23):2727-41. doi: 10.1001/jama.295.23.joc60074. Epub 2006 Jun 5.
10
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.一项基于人群的淋巴结阴性患者肿瘤基因表达与乳腺癌死亡风险的研究。
Breast Cancer Res. 2006;8(3):R25. doi: 10.1186/bcr1412. Epub 2006 May 31.
Zotero 插件